Switzerland's PregLem--which has programs for gynecological conditions and infertility--has raised $26 million in its first round and struck a licensing deal with Ipsen. Sofinnova Partners led the round and was joined by NeoMed Management and MVM Life Science Partners. No terms were announced in the Ipsen deal, but PregLem gains development and commercialization rights for a range of compounds involved in reproductive medicine.
- see this release
- here's the AFX report on PregLem
- and here's the report from Private Equity Hub
ALSO: Ista Pharmaceuticals is raising $36.8 million in a private financing deal. Release